PTHS Chromocell Therapeutics Corp

NYSE chromocell.com


$ 25.39 $ -2.02 (-7.37 %)    

Friday, 21-Nov-2025 15:52:29 EST
QQQ $ 591.24 $ 3.91 (0.67 %)
DIA $ 462.79 $ 3.32 (0.72 %)
SPY $ 659.50 $ 4.49 (0.69 %)
TLT $ 89.47 $ -0.20 (-0.22 %)
GLD $ 373.40 $ -0.59 (-0.16 %)
$ 29
$ 27.41
$ 24.93 x 100
$ 26.30 x 100
$ 25.39 - $ 27.01
$ 5.10 - $ 54.29
30,469
na
88.79M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-16-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target fro...

Core News & Articles

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the analyst consensus estimate of ...

Core News & Articles

Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces...

Core News & Articles

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.38) per share which beat the analyst consensus estimate of $(...

 pelthos-therapeutics-launches-first-at-home-prescription-gel-for-highly-contagious-skin-disease

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little a...

Core News & Articles

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has co...

Core News & Articles

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION